[68Ga]Ga-PSMA-11 PET/CT and [18F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial
[<sup>68</sup>Ga]Ga-PSMA-11 PET/CT revealed superior diagnostic performance to [<sup>18</sup>F]FCH PET/CT in patients with recurrent PCa, specifically with very low PSA levels ≤ 1 ng/ml. Moreover, it led to more accurate staging and clinical management of the disease. [<sup>18</sup>F]FCH PET/CT may play a complementary role in rare, select high-risk cases with negative [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT and ongoing ADT.
Authors
- Marcus Hacker (ORCID: https://orcid.org/0000-0002-4222-4083)
- Mohsen Beheshti (ORCID: https://orcid.org/0000-0003-3918-3812)
- Wolfgang Loidl (ORCID: https://orcid.org/0000-0001-9354-5728)
- Malihe Shahbazi-Akbari
- Werner Langsteger
Institutions
- Paracelsus Medical University (AT)
- Kepler Universitätsklinikum (AT)
- Krankenhaus der Elisabethinen (AT)
- AGO Austria (AT)
- Tehran University of Medical Sciences (IR)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Molecular Imaging and Biology
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1007/s11307-025-02020-5
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Paracelsus Medizinische Privatuniversität